Skip to main content
. Author manuscript; available in PMC: 2021 May 28.
Published in final edited form as: J Thorac Oncol. 2019 May 20;14(9):1583–1593. doi: 10.1016/j.jtho.2019.05.009

Table 4.

Final multivariable competing-risk regression models, adjusted by stage, for recurrence and lung cancer–specific death in the overall, large cell neuroendocrine carcinoma, and small cell lung carcinoma cohorts

Any recurrence Lung cancer-specific death

Cohort, Variable SHR (95% CI) p SHR (95% CI) p
MODEL 1 Overall (n=188)
 Histologic subtype (vs LCNEC)
  AC 0.81 (0.45, 1.46) 0.480 0.55 (0.27, 1.11) 0.094
  SCLC 0.47 (0.23, 0.98) 0.019 0.59 (0.32, 1.11) 0.1
 Sex: male (vs. female) 2.05 (1.24, 3.38) 0.005 1.96 (1.09, 3.53) 0.024
 Smoking pack-years (per 1 pack/year increase) 1.01 (1.00, 1.01) 0.003
 Adjuvant therapy (vs no adjuvant) 1.72 (0.96, 3.08) 0.068 1.29 (0.69, 2.42) 0.4
 Lymphatic invasion (vs absent) 2.21 (1.20, 4.09) 0.011 2.85 (1.36, 5.98) 0.005
 STAS (present vs absent) 2.85 (1.73, 4.68) <0.001 2.72 (1.57, 4.70) <0.001
MODEL 2: LCNEC (n=93)
 Sex: male (vs. female) 2.13 (1.10, 4.12) 0.026 2.20 (1.10, 4.40) 0.025
 Adjuvant therapy (vs no adjuvant) 1.51 (0.69, 3.3) 0.3 0.91 (0.45, 1.86) 0.8
 Lymphatic invasion (vs absent) 2.49 (1.18, 5.27) 0.017 3.17 (1.38, 7.28) 0.006
 STAS (present vs absent) 2.39 (1.26, 4.54) 0.008 2.42 (1.21, 4.84) 0.012
MODEL 3: SCLC (n=57)
 Smoking pack-years (per 1 pack/year increase) 1.02 (1.00, 1.04) 0.017
 Adjuvant therapy (vs no adjuvant) 6.61 (1.68, 25.92) 0.007
 Lymphatic invasion (vs absent) 4.14 (0.82, 20.87) 0.086
 Pleural invasion (vs absent) 3.67 (1.19, 11.34) 0.024
 Necrosis percentage (per 1% increase) 1.03 (1.01, 1.05) 0.007 1.04 (1.01, 1.07) 0.003
 STAS (present vs absent) 2.63 (0.86, 8.03) 0.090 4.06 (1.33, 12.35) 0.014

Significant p values are shown in bold. AC, atypical carcinoid; CI, confidence interval; LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell carcinoma; SHR, subhazard ratio; STAS, spread through air spaces.